Tue. 14 May 2024, 8:19am ET
Benzinga
Earnings, News
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 10.53 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $148.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 196.00 percent. This is a 123.70 percent increase over sales of $66.16 thousand the same period last year.